

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

Giredestrant with everolimus for treating oestrogen receptor positive HER2 negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576

# **Provisional Stakeholder List**


Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Roche (giredestrant)	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
Patient/carer groups Black Health Agency for Equality Breast Cancer Now Breast Cancer UK Cancer Black Care Independent Cancer Patients Voice Inflammatory Breast Cancer (IBC) Network UK Lobular Breast Cancer UK Macmillan Cancer Support Maggie's Centres Make 2nds Count MeT UP UK Prevent Breast Cancer South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care  Healthcare professional groups Association of Breast Surgery Association of Cancer Physicians British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society of Interventional Radiology Cancer Research UK	<ul> <li>Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>NHS Wales Joint Commissioning Committee</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> <li>Possible comparator companies</li> <li>AAH Pharmaceuticals (exemestane)</li> <li>Accord UK (capecitabine, docetaxel, everolimus, exemestane, gemcitabine, paclitaxel)</li> <li>Alliance Healthcare (Distribution) (exemestane)</li> <li>Amarox (capecitabine, letrozole, anastrazole, gemcitabine)</li> <li>AstraZeneca (capivasertib, daptotamab deruxtecan, fulvestrant, olaparib, tamoxifen, anastrazole)</li> </ul>
<ul> <li>Royal College of General Practitioners</li> </ul>	

Provisional stakeholder list for the evaluation of Giredestrant with everolimus for treating oestrogen receptor positive HER2 negative advanced breast cancer after CDK 4 6 inhibitor and endocrine treatment ID6576



#### **Provisional Consultees Provisional Commentators (no right to** submit or appeal) Aurobindo Pharma (tamoxifen, Royal College of Nursing Royal College of Pathologists anastrazole) Royal College of Physicians **Bristol Myers Squibb Pharmaceuticals** (paclitaxel) Royal College of Radiologists Cipla EU (letrozole) Royal Pharmaceutical Society Consilient Health (docetaxel, Royal Society of Medicine exemestane, gemcitabine, vinorelbine) Society and College of Radiographers Dr Reddy's Laboratories (capecitabine, **UK Breast Cancer Group** everolimus, fulvestrant, gemcitabine) **UK Clinical Pharmacy Association** Eli Lilly (abemaciclib, imlunestrant) UK Oncology Nursing Society Ethypharm UK (everolimus) Fresenius Kabi (gemcitabine, paclitaxel) Others Genus Pharmaceuticals (fulvestrant. Department of Health and Social Care paclitaxel) NHS England Gilead Sciences (Sacituzumab govitecan) **Glenmark Pharmaceuticals** (capecitabine, exemestane, fulvestrant, letrozole, gemcitabine) Hospira UK (docetaxel, gemcitabine, paclitaxel) Kent Pharma UK (exemestane, fulvestrant) Martindale Pharmaceuticals (everolimus) Medac (vinorelbine) Medical Valley Invest (fulvestrant) Medihealth (Northern) (exemestane) Menarini Stemline (elacestrant) Morningside Healthcare (capecitabine, exemestane) MSD (pembrolizumab) Mylan (exemestane, tamoxifen, anastrazole) Novartis (alpelisib, everolimus, ribociclib, letrozole) Pfizer (docetaxel, exemestane, gemcitabine, palbociclib, paclitaxel, talazoparib) Phoenix Healthcare Distribution (exemestane) Pierre Fabre (vinorelbine) Rivopharm (exemestane) Roche (inavolisib)

Provisional stakeholder list for the evaluation of Giredestrant with everolimus for treating oestrogen receptor positive HER2 negative advanced breast cancer after CDK 4 6 inhibitor and endocrine treatment ID6576



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul> <li>Rosemont Pharmaceuticals (tamoxifen)</li> <li>Sandoz (everolimus, fulvestrant)</li> <li>Seacross Pharmaceuticals (docetaxel, fulvestrant, paclitaxel, anastrazole)</li> <li>Sigma Pharmaceuticals (exemestane)</li> <li>Sun Pharmaceutical Industries Europe (fulvestrant, gemcitabine, letrozole, anastrazole)</li> <li>Synchrony Pharma (gemcitabine)</li> <li>Teva UK (everolimus, fulvestrant, paclitaxel)</li> <li>Tillomed Laboratories (tamoxifen)</li> <li>Thornton &amp; Ross (fulvestrant)</li> <li>Viatris UK Healthcare (exemestane)</li> <li>Waverley Pharma Europe (capecitabine)</li> <li>Wockhardt (tamoxifen)</li> <li>Zentiva (exemestane, fulvestrant)</li> </ul>
	Relevant research groups  Against Breast Cancer Breast Cancer Hope Cochrane Breast Cancer Group Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Pro-Cancer Research Fund  Associated Public Health groups Public Health Wales UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the

Provisional stakeholder list for the evaluation of Giredestrant with everolimus for treating oestrogen receptor positive HER2 negative advanced breast cancer after CDK 4 6 inhibitor and endocrine treatment ID6576

Issue date: November 2025



evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.